Mutations in EPHB4 cause human venous valve aplasia.

Area of Science:

• Cardiovascular Biology
• Developmental Biology
• Molecular Genetics

Background:

• Venous valve (VV) failure is a primary cause of chronic venous insufficiency, yet its molecular regulation remains unclear.
• Patients with mutations in the receptor tyrosine kinase EPHB4 exhibit lymphatic anomalies and venous insufficiency, but the impact on VVs is unknown.

Purpose of the Study:

• To investigate the role of EPHB4 and its ligand ephrinB2 in venous valve development and identify the cause of venous anomalies in EPHB4 mutation patients.

Main Methods:

• Quantitative ultrasound to assess VV structure and function in patients with EPHB4 mutations.
• Mouse models with GFP reporters for ephrinB2 and conditional deletion of Ephb4 and Efnb2 alleles to study gene expression and developmental phenotypes.

Main Results:

• Patients with EPHB4 mutations showed significant VV aplasia and deep venous reflux.
• EphB4 and ephrinB2 expression were dynamically regulated during valve formation.
• Efnb2 deletion impaired valve-forming cell organization, polarity, proliferation, and disrupted connexin expression, leading to deficient valve development.

Conclusions:

• EPHB4 signaling is crucial for venous valve development by regulating endothelial cell organization and connexin expression.
• Mutations in EPHB4 represent a novel cause of primary human venous valve aplasia and chronic venous insufficiency.